MARKET NEWS

SunGen Pharma & Athenex Pharmaceutical Division Announce Injection Product Launch
CURE Pharmaceutical Expands US DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant
Imugene Announces First Patient Dosed in Open-Label Phase 2 Study
Santhera Completes Patient Enrollment in Phase IV Long-term Study
Cambrex Completes Expansion & Manufacturing Capability Upgrades
Biogen Enters Agreement to Sell Its Large-Scale Biologics Manufacturing Site

  FEATURED EDITORIAL

  COMPANY PROFILE

 

Gateway Analytical is an innovative analytical laboratory that specializes in providing expert testing services to the pharmaceutical, medical device, and materials science industries. Built with quality as our cornerstone and timeliness, and customer service as our core values, we are able to offer project turnaround in as fast as 24 hours in a GMP-compliant environment. Our new, fully equipped 8,000-sq-ft laboratory space features HEPA-filtered controlled environments, ISO 9001 and ISO 17025 accreditations, specialized sample preparation capabilities, and a dedicated space for handling cytotoxic drug materials. Gateway is able to provide industry leading materials analysis services tailored to support a variety of unique drug development projects. Click here for more.

 

  EXCLUSIVE ONLINE CONTENT

Proper Fill & Finish in Clinical Development Requires  a Comprehensive Approach

Proper Fill & Finish in Clinical Development Requires  a Comprehensive Approach

For pharma and biotech companies both large and small, the challenges involved in the fill and finish process of drugs for clinical development and scale-up continue to present new challenges.

Ajinomoto Bio-Pharma Services Announces Capital Expansion to Fuel Growth

Ajinomoto Bio-Pharma Services Announces Capital Expansion to Fuel Growth

Ajinomoto Bio-Pharma Services recently provided an update on several of its capital projects currently underway in both the United States and Belgium. 

Procarta Announces Significant Investment for New Class of Antibiotics

Procarta Announces Significant Investment for New Class of Antibiotics

Procarta Biosystems recently announced $1.7 million of new funding from the Novo Holdings REPAIR Impact Fund to support development of novel therapies to combat antimicrobial resistance (AMR).

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 27 – Parenteral Contract Manufacturing
April 3 – Polymers & Biomaterials